by Eric Christianson | Dec 31, 2025 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Pimavanserin is a unique antipsychotic with a very specific niche in clinical practice. It is most commonly used for Parkinson’s disease psychosis, and its pharmacology, benefits, and risks are frequently tested and clinically misunderstood. In this blog post,...
by Eric Christianson | Dec 10, 2025 | Psychiatry and Addiction Medicine Case Studies
I recently came across a case scenario of drug induced akathisia. It is important to remember that aripiprazole is one of the most common causes of this adverse effect. Here’s the case – LY is a 72-year-old man with a 10-year history of Parkinson’s disease...
by Eric Christianson | Apr 2, 2025 | Neurology, Pain, and Musculoskeletal Medication and Disease State Clinical Pearls
Sinemet, a key medication for managing Parkinson’s disease, combines carbidopa and levodopa to improve motor symptoms such as tremors, stiffness, and slow movement. However, Sinemet is known for its potential drug interactions, which can affect its efficacy and lead...
by Eric Christianson | Feb 23, 2022 | Medication and Disease State Clinical Pearls For Pharmacists
Pharmacists are no strangers to neurodegenerative disease. However, Parkinson’s cases present great difficulty to patients and clinicians, as our medical world lacks a solid understanding of the disease in comparison to other conditions. After Alzheimer’s disease,...
